Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by MPM Bioimpact LLC

MPM Bioimpact LLC lessened its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 24.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,106,851 shares of the company's stock after selling 358,950 shares during the period. MPM Bioimpact LLC owned about 1.55% of Zentalis Pharmaceuticals worth $3,354,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ZNTL. Corton Capital Inc. bought a new position in Zentalis Pharmaceuticals during the 4th quarter worth approximately $32,000. Captrust Financial Advisors acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth approximately $33,000. Prudential Financial Inc. acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth approximately $39,000. Cerity Partners LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth approximately $40,000. Finally, Ieq Capital LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth approximately $46,000.

Insider Activity

In other news, Director Scott Dunseth Myers purchased 21,000 shares of the stock in a transaction dated Wednesday, April 30th. The shares were bought at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the transaction, the director now owns 281,192 shares in the company, valued at $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ZNTL. Wedbush reiterated a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday. Wells Fargo & Company dropped their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday. Finally, UBS Group dropped their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $8.24.

Zentalis Pharmaceuticals Trading Down 1.2%

ZNTL traded down $0.02 during trading hours on Monday, hitting $1.25. The company's stock had a trading volume of 350,964 shares, compared to its average volume of 1,413,601. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $13.00. The firm has a market capitalization of $89.58 million, a PE ratio of -0.50 and a beta of 1.81. The company has a 50-day simple moving average of $1.44 and a 200 day simple moving average of $2.33.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, meeting the consensus estimate of ($0.67). Research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.